Patients must be able to tolerate oral medications by mouth, and not have a gastrointestinal illness that would preclude absorption of olaparib
Inability to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation. Patients should not have gastrointestinal illnesses that would preclude the absorption of BGB-290, which is an oral agent.
Patients must be able to tolerate oral medications and not have gastrointestinal processes that would preclude absorption of olaparib
Any known gastrointestinal disorders which would preclude oral administration of 5-azacitidine
COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Patients must be able to swallow oral medications (capsules) without chewing, breaking, crushing, opening or otherwise altering the product formulation
COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Known history of gastrointestinal illnesses that would preclude the absorption of ONC201, which is an oral agent
COHORT 2: TRIPLE NEGATIVE BREAST CANCER: Patients must be able to swallow oral medications (capsules) without chewing, breaking, crushing, opening or otherwise altering the product formulation
COHORT 2: TRIPLE NEGATIVE BREAST CANCER: Known history of gastrointestinal illnesses that would preclude the absorption of ONC201, which is an oral agent
COHORT 3: ENDOMETRIAL CANCER: Patients must be able to swallow oral medications (capsules) without chewing, breaking, crushing, opening or otherwise altering the product formulation
COHORT 3: ENDOMETRIAL CANCER: Known history of gastrointestinal illnesses that would preclude the absorption of ONC201, which is an oral agent
Patients must be able to swallow oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
Patients must be able to swallow and retain oral medications and be without gastrointestinal illnesses that would preclude absorption of AZD8186
Patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
Able to tolerate oral medications and no GI illnesses that would preclude absorption of olaparib
UROTHELIAL CARCINOMA EXPANSION COHORT: Patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of olaparib
Ability to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation. Patients should not have gastrointestinal illnesses that would preclude the absorption of olaparib, which is an oral agent. For the gastric cancer cohort, patients with a full or partial gastrectomy will be permitted.
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nPatients must be able to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation; they should not have gastrointestinal illnesses that would preclude the absorption of cediranib or olaparib, which are oral agents
PHASE II STUDY COHORT 1 OVARIAN CANCER ELIGIBILITY CRITERIA (MEDI+O, MEDI+C AND MEDI+O+C): \r\nPatients must be able to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation; they should not have gastrointestinal illnesses that would preclude the absorption of cediranib or olaparib, which are oral agents
PHASE II STUDY COHORT 5 TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nPatients must be able to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation; they should not have gastrointestinal illnesses that would preclude the absorption of cediranib or olaparib, which are oral agents
PHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nPatients must be able to swallow oral medications without chewing, breaking, crushing, opening or otherwise altering the product formulation; they should not have gastrointestinal illnesses that would preclude the absorption of cediranib which are an oral agent
Patients must be able to swallow and retain oral medications and without gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
Able to swallow and retain oral medications and without gastrointestinal (GI) illnesses that would preclude absorption of cediranib or olaparib
Patient is able to tolerate oral medications and does not have gastrointestinal illnesses that would preclude absorption of either olaparib or BKM120 or BYL719
Able to swallow and retain oral medications and without gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
Patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
Patients must be able to swallow and tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of AZD2014, AZD5363, or olaparib (e.g. uncontrolled nausea, vomiting, or diarrhea; malabsorption syndrome; ulcerative disease)
Patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of GSK1120212 and GSK2141795
Any known gastrointestinal disorders which would preclude oral administration of 5-azacitidine
Patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
Patients must be able to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation
Patients must be able to swallow and tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of AZD1775 (e.g. uncontrolled nausea, vomiting, or diarrhea; malabsorption syndrome; ulcerative disease); Note: patient may not have a percutaneous endoscopic gastrostomy (PEG) tube or be receiving total parenteral nutrition (TPN)
Patients must be able to swallow and tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of BMN 673 (e.g. uncontrolled nausea, vomiting, or diarrhea; malabsorption syndrome; ulcerative disease)